moatshark My

All holdings

Medpace Holdings

MEDP

Source: the SEC Form 13F filings of the managers we follow, latest for Q3 2026. How we use them

Managers holding
4
In their latest 13F (Q3 2026)
See who
Value held
$283m
Combined value at quarter end
Last quarter
1 bought
3 sold or trimmed
Fund portfolios
4
Funds holding it
See which
Price at Q2 ’26 end
$529.59
+10.3% in the quarter

Prices here are quarter-end prices implied by the 13F filings. Today’s price on Yahoo Finance

Share price change by quarter

-19.0%Q3 ’24
-0.5%Q4 ’24
-8.3%Q1 ’25
+3.0%Q2 ’25
+63.8%Q3 ’25
+9.2%Q4 ’25
-14.5%Q1 ’26
+10.3%Q2 ’26
Q3 ’24: -19.0%; Q4 ’24: -0.5%; Q1 ’25: -8.3%; Q2 ’25: +3.0%; Q3 ’25: +63.8%; Q4 ’25: +9.2%; Q1 ’26: -14.5%; Q2 ’26: +10.3%

Change in the quarter-end price implied by managers’ 13F filings, adjusted for stock splits. Excludes dividends.

Managers holding it, by quarter

4Q4 ’23
4Q1 ’24
4Q2 ’24
4Q3 ’24
5Q4 ’24
5Q1 ’25
5Q2 ’25
5Q3 ’25
5Q4 ’25
4Q1 ’26
4Q2 ’26
0Q3 ’26
Q4 ’23: 4; Q1 ’24: 4; Q2 ’24: 4; Q3 ’24: 4; Q4 ’24: 5; Q1 ’25: 5; Q2 ’25: 5; Q3 ’25: 5; Q4 ’25: 5; Q1 ’26: 4; Q2 ’26: 4; Q3 ’26: 0

Counts the managers on this site whose 13F for that quarter includes Medpace Holdings.

Who holds it

Each manager’s latest 13F, sorted by how much of their portfolio it is. Changes are against their previous quarter.

Managers holding Medpace Holdings
Giverny Capital4.5%$134m$134mTrimmed -0.8%12 qtrs
Vulcan Value Partners2.3%$75.1m$75.1mTrimmed -30%21 qtrs
Mairs & Power0.4%$45.9m$45.9mAdded +1.2%16 qtrs
Fundsmith0.2%$27.7m$27.7mTrimmed -16%7 qtrs

Download the holders: CSV · JSON · Markdown

Directors buying and selling

Open-market trades by directors, officers and 10% holders over the last 12 months. How this works
From their Form 4 filings with the SEC. Grants, option exercises and shares sold to pay tax are left out.
Insider purchases and sales of Medpace Holdings
Bought or soldFiling
30 Sep 2026Troendle August J.President & CEO▼ Sold21,966$625.47$13.7mForm 4
29 Sep 2026Troendle August J.President & CEO▼ Sold26,701$621.02$16.6mForm 4
28 Sep 2026Troendle August J.President & CEO▼ Sold2,410$620.07$1.5mForm 4
25 Sep 2026Troendle August J.President & CEO▼ Sold154$620.60$96kForm 4
24 Sep 2026Troendle August J.President & CEO▼ Sold27,833$621.33$17.3mForm 4
23 Sep 2026Troendle August J.President & CEO▼ Sold16,083$628.64$10.1mForm 4
22 Sep 2026Troendle August J.President & CEO▼ Sold49,018$628.11$30.8mForm 4
21 Sep 2026Troendle August J.President & CEO▼ Sold21,883$623.29$13.6mForm 4
17 Sep 2026Troendle August J.President & CEO▼ Sold10,880$620.40$6.7mForm 4
16 Sep 2026Troendle August J.President & CEO▼ Sold8,770$621.29$5.4mForm 4
15 Sep 2026Troendle August J.President & CEO▼ Sold15,971$620.84$9.9mForm 4
27 Aug 2026Troendle August J.President & CEO▼ Sold650$620.27$403kForm 4
26 Aug 2026Troendle August J.President & CEO▼ Sold4,000$620.03$2.5mForm 4
26 Aug 2026Kraft Robert O.Director▼ Sold3,858$617.81$2.4mForm 4
25 Aug 2026Troendle August J.President & CEO▼ Sold673$620.38$418kForm 4
24 Aug 2026Troendle August J.President & CEO▼ Sold1,983$620.23$1.2mForm 4
21 Aug 2026Troendle August J.President & CEO▼ Sold13,995$624.45$8.7mForm 4
20 Aug 2026Troendle August J.President & CEO▼ Sold27,174$618.79$16.8mForm 4
20 Aug 2026Brady Kevin M.CFO & Treasurer▼ Sold3,400$625.24$2.1mForm 4
19 Aug 2026Troendle August J.President & CEO▼ Sold15,609$606.47$9.5mForm 4

About the company

Sector
Health care · Services-Commercial Physical & Biological Research
Incorporated in
Delaware
Financial year ends
31 December
Shares outstanding
28m at 17 Jul 2026
SEC filings
Annual reports and other filings on EDGAR

Revenue and profit

$359m2015
$422m2016
$436m2017
$705m2018
$861m2019
$926m2020
$1.1bn2021
$1.5bn2022
$1.9bn2023
$2.1bn2024
$2.5bn2025
2015: $359m; 2016: $422m; 2017: $436m; 2018: $705m; 2019: $861m; 2020: $926m; 2021: $1.1bn; 2022: $1.5bn; 2023: $1.9bn; 2024: $2.1bn; 2025: $2.5bn
Medpace Holdings revenue and net income by year
YearRevenueNet income
2025$2.5bn$451m
2024$2.1bn$404m
2023$1.9bn$283m
2022$1.5bn$245m
2021$1.1bn$182m
2020$926m$145m
2019$861m$100m
2018$705m$73.2m
2017$436m$39.1m
2016$422m$13.4m
2015$359m−$8.7m

From the company’s XBRL financial statements filed with the SEC, for each financial year. Gaps mean the company didn’t report that figure in a standard form.

In fund portfolios

US-registered funds run by these managers that hold Medpace Holdings, from their latest N-PORT filings.

Funds holding Medpace Holdings
Vulcan Value Partners Small Cap FundVulcan Value Partners4.5%$3.7m31 Jul 2026
Vulcan Value Partners FundVulcan Value Partners2.5%$5.7m31 Jul 2026
Mairs & Power Small Cap FundMairs & Power1.5%$4.0m30 Jun 2026
Mairs & Power Growth FundMairs & Power0.6%$32.3m30 Jun 2026